Replies to post #185967 on Elite Pharmaceuticals Inc (ELTP)

[CMDawg]

It’s about to get fun. One way or another.

[NASDAQ2020]

20 Pathways to DollarLand

Any One of these will get us there in 2019-2020
1.) SunGen ANDA #2 (Avatar) $1.6 Billion market 4 competitors: Approval Imminent
2.) SunGen ANDA #5 greater than $1.6 Billion market FDA filing imminent
3.) SequestOx® First ever Immediate Release ADF labeled opiod with ORAL, IV, and Nasal ADF Labeling (chewing) The Holy Grail of IR opioids
4.) Approval/Launch of First Ever Abuse Deterrent Generic Reformulated OxyContin® filed watch for approval in 2019
5.) First to market Generic ER 2 bead ADF Oxycodone ELI-201
6.) Unique-Novel ADF Without Naltrexone pilot study completed and
90% cheaper than the competitions ADF
7.) Launch first four SunGen generics (2016) ($4 Billion combined markets) The two SunGen deals have a combined market worth $6 billion
8.) Buyout / Acquisition
9.) BP Partnership for entire ADF line
10.) Uplisting to NASDAQ exchange
11.) Merger
12.) Complete PH III trials for the first ever 24 hour
13.) Generic of Reformulated Opana® ER
14.) First ADF opiod for Chinese Pain Market --PuraCap/Humanwell
15.) Canadian Approval of SequestOx® - patents in place
16.) FDA accepts citizen petition urging the FDA to phase out oral prescription opioid analgesics that lack abuse-deterrent properties
17.) Launch additional 2017 SunGen generics brings the market to $6 billion
18.) Chinese approval of SequestOx® Chinese meeting Feb 2017
19.) European approval of AD oxycodone/opiod - patents in place
20.) Undisclosed Surprise

[NASDAQ2020]

20 Pathways to DollarLand

Any One of these will get us there in 2019-2020
1.) SunGen ANDA #2 (Avatar) $1.6 Billion market 4 competitors: Approval Imminent
2.) SunGen ANDA #5 greater than $1.6 Billion market FDA filing imminent
3.) SequestOx® First ever Immediate Release ADF labeled opiod with ORAL, IV, and Nasal ADF Labeling (chewing) The Holy Grail of IR opioids
4.) Approval/Launch of First Ever Abuse Deterrent Generic Reformulated OxyContin® filed watch for approval in 2019
5.) First to market Generic ER 2 bead ADF Oxycodone ELI-201
6.) Unique-Novel ADF Without Naltrexone pilot study completed and
90% cheaper than the competitions ADF
7.) Launch first four SunGen generics (2016) ($4 Billion combined markets) The two SunGen deals have a combined market worth $6 billion
8.) Buyout / Acquisition
9.) BP Partnership for entire ADF line
10.) Uplisting to NASDAQ exchange
11.) Merger
12.) Complete PH III trials for the first ever 24 hour
13.) Generic of Reformulated Opana® ER
14.) First ADF opiod for Chinese Pain Market --PuraCap/Humanwell
15.) Canadian Approval of SequestOx® - patents in place
16.) FDA accepts citizen petition urging the FDA to phase out oral prescription opioid analgesics that lack abuse-deterrent properties
17.) Launch additional 2017 SunGen generics brings the market to $6 billion
18.) Chinese approval of SequestOx® Chinese meeting Feb 2017
19.) European approval of AD oxycodone/opiod - patents in place
20.) Undisclosed Surprise

[NASDAQ2020]

Elite in the Top 38% of ALL publicly traded companies that are profitable.




https://www.consultantsmind.com/2018/03/04/choosing-stocks

[NASDAQ2020]

Elite only co. to become profitable during the pandemic.

“We Got This”

[NASDAQ2020]

All ELTP shares are being converted to common.
Everyone converting their cash to common shares.
Employees taking shares in lieu of cash.

It's On !!!!!!!!

[NASDAQ2020]

GENERIC ADDERALL XR
ER CNS stimulant
Approved Dec 2019
Got API thru end of calendar 2020
Got Quota to deal with US shortage
Launched Mar 2020
(((( $1.5 Billion market )))) per IQVIA
Milestone and revenues to follow
$$$$ This generics competition are ALL “Authorized “ generics which pay royalties to the branded. Elite does not have to pay those royalties which gives Elite an edge on the competition $$$$$

Elite has officially become * Cash Flow Positive * with The Monster Launched (Adderall XR)

Monster Revenues slows/halts dilution
Finances all future R&D
Removes all going concerns
Pays for trials for unique ADF that is cheaper than those with Naltrexone
Pays for Elite’s wholly owned Godzilla - an undisclosed CNS stimulant with a $2.2 Billion Market per IQVIA
Massive organic growth

Generic Adderall XR is jointly owned and the second product approval for Elite and Mikah Pharma LLC collaboration. Elite will manufacture and package the product on a cost-plus basis. Lannett Company, Inc. will be the exclusive U.S. distributor.

"We are pleased to have received approval of this second product” said Nasrat Hakim, President and CEO of Elite and Mikah.
The Launch of this product was Elite’s top priority."


Quote Nasrat: .

“ This is an outstanding product for us once we get an approval because we will be the fifth in this arena, and even if there were more people than that and we've got just 10% of that market, that's $160 million, a $160 million in revenues will do wonders to Elite stock. Even if we cut it in half between us and SunGen and you take out the actual cost which is another half and walk away with only $40 million, that will take our market cap from 80 million which is today to $800 million with one product only."

Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate, Extended- Release Capsules

“Game Changer”

ELTP

[NASDAQ2020]

What is the date for next earnings?

tIA

ELTP

[NASDAQ2020]

GodZilla -THE GRAND DADDY OF THEM ALL Bigger than Adderall XR undisclosed ER CNS stimulant Documented $ 2.176 billion IQVIA market

This is the Largest Elite product Yet !!!*****
All resources on this one. File in 20-21
100% owned by Elite.

ELTP

[NASDAQ2020]

137% YOY

5 quarters of double and triple digit growth!,,

Record quarterly revenues .

Cash Flow Positive

$830,000 profit

Isradipine has potential upside

Elite streamlining using SAP technology

No obligation to SunGen for GodZilla the $1.5 Billion CNS stinulant.

Loxapine API coming from India not China

Loxapine on shortage list

Debt to market cap : 7%

“Elite is attractive for Merger or BuyOut”

Adderall IR and ER have strong UPSIDE POTENTIAL $2 billion combined market

New Equipment for production line - NEW 30 cubic foot V-blender
NEW higher speed tablet press.

Upgraded the Packaging Line - capacity increased by 25%

Back to school Adderall

Lannett continues to penetrate markets

Walgreens Largest Customer 15% of market

$75 million tax credit, no taxes on first $75 million profit.

Loxapine $5 million IQVIA market

[NASDAQ2020]

Monster Earnings !

ELTP

[NASDAQ2020]

—-Actual Documented Adderall Combined IQVIA Markets surpassing $2 Billion for Elite’s XR and IR. ( according to IQVIA ) 15.7% CAGR ELTP has Minimal competitors. $7+ million sold last quarter alone. Up 137% YOY, Now 53% Quarter Over Quarter!!
Branded sales rapidly falling as generics take their place.
Huge profit splits imminent.
ELTP
Elite has the best price structure of the competition, they are gobbling up their cut of the $2 Billion

Adderall market has surpassed $2 billion and still growing due to US shortage

The high demand and shortage has us over $2 billion.

The most expensive medications on the list that make the most money for their manufacturers are:
--Concerta (for ADHD) –$2.176 billion IQVIA
--Adderall (for ADHD) – $1.914 billion IQVIA

QUOTE: "We would like to thank the good folks at IQVIA for providing the data."

https://psychcentral.com/blog/top-25-psychiatric-medications-for-2018


A shout goes out to the good folks at IQVIA for providing the data !!

[NASDAQ2020]

SunGen/MIKAH/Elite ANDAs

Actual IQVIA market values

1. Adderall IR IQVIA $400 million market ***LAUNCHED*** partnered with MIKAH
2. ER CNS stimulant IQVIA $1.5 Billion market  ***LAUNCHED*** Mar 2020*** partnered with MIKAH
3. IR Antibiotic IQVIA $94 million market *** Filed - Approval expected In 2020*** under negotiations for acquisition
4. Undisclosed antidepressant under negotiations for acquisition
5. CNS ER combination stimulant IQVIA $2.2 Billion market 100% owned by Elite

All resources on #1- #5 currently.

Just 4 of the CNS drugs have a combined Market of

$3.0+ Billion Combined IQVIA Market


“We would like to thank the good folks at IQVIA for providing the data."

[NASDAQ2020]

Sorry I rounded off the IQVIA market value.
I did not think it would matter to most folks.


GodZilla -THE GRAND DADDY OF THEM ALL Bigger than Adderall XR undisclosed ER CNS stimulant Actual $ 2.176 billion IQVIA market

This is the Largest Elite product Yet !!!*****
All resources on this one. File in 2021
100% owned by Elite.

Just in time for the spike in ADHD cases.
ELTP

[NASDAQ2020]

Accumulating for the assent.
ELTP

[NASDAQ2020]

SunGen/MIKAH/Elite ANDAs

Actual IQVIA market values

1. Adderall IR IQVIA $400 million market ***LAUNCHED*** partnered with MIKAH
2. ER CNS stimulant IQVIA $1.5 Billion market  ***LAUNCHED*** Mar 2020*** partnered with MIKAH
3. IR Antibiotic IQVIA $94 million market *** Filed - Approval expected In 2020*** under negotiations for acquisition
4. Undisclosed antidepressant under negotiations for acquisition
5. CNS ER combination stimulant IQVIA $2.2 Billion market 100% owned by Elite

All resources on #1- #5 currently.

Just 4 of the CNS drugs have a combined Market of

$3.0+ Billion Combined IQVIA Market


“We would like to thank the good folks at IQVIA for providing the data."

[NASDAQ2020]

Updates on development projects will be provided upon achieving key milestones.

[NASDAQ2020]

Its about to Get Real !!

ELTP

[NASDAQ2020]

The Accumulation Continues

$$$$$$$$$$$$$

ELTP

Locked $ Loaded !!!

[NASDAQ2020]

Elite —-39 Countries via new partner